Table 1 Clinical features after treatment with infliximab.

	Eye	Diagnosis	Clinical features of systemic disease	Initial visual acuity (VA)	Inflammatory activity before starting treatment with infliximab (using SUN citeria[9]				Activity 3 months from start of infliximab	Activity at 6 months	Activity at 9 months*/ 12 months†	Dose of infliximab and additional events	Final VA
					AC (grade cells)	Vitreous haze (BIO)	CMO Y/N	Number of active joints (n)
A	RE	Psoriatic JIA	Polyarthritis,	0.8	+1	0	Y		Improved activity and CMO	Inactive	Inactive†	3 mg/kg	0.2
		HLA B27+	Psoriasis						0 joints	Improved CMO	No CMO†	1×ST	–0.2
	LE	ANA−	Nail dystrophy	–0.1	No inflammatory activity			12		1 joint	0 joints†
			Osteoporosis
			Delayed growth
B	RE	Psoriatic JIA	Polyarthritis	–0.2	No inflammatory activity				Improved activity	Worse activity	NA	6 mg/kg	0
			Psoriasis									1×ST
		HLA B27+	Growth failure					3	0 joints	0 joints		1x intravit
	LE	ANA−	Nail dystrophy, uveitis	2.3	+1	+3	N					LVit'y	2.3
C	RE	Systemic JIA	Polyarthritis	0.2	+2	0	N		Unchanged	Improved activity	Worse†	6 mg/kg	0.2
	LE	ANA−		0.6	+2	0	N	2	activity		4 joints†		0.2
									0 joints	0 joints
D	RE	Sarcoidosis	Sarcoid polyarthritis, renal, skin, growth failure	0.2	+1	0	N		Unchanged activity	Improved activity	Improved activity*	6 mg/kg	0.3
												R Vit'y
	LE			0.6	+1	0	N	2	0 joints	1 joint	0 joints*	R intravit	0.2
E	RE	Psoriatic JIA	Previous posterior fossa medulloblastoma	0.2	+2	0	N		Improved activity	Inactive eyes	Inactive eyes*	3 mg/kg	0.2
	LE	ANA−		1.0	+1	0	N	1	0 joints	0 joints	0 joints*	L cataract extraction	0.1
F	RE	Multisystem granulomatous disease	Polyarthritis, epitheloid granulomas of skin, small intestine involvement	0.1	+1	0	N					3 mg/kg	0.1
		ANA+							Inactive.	Inactive
	LE	ACE+		0.1	+2	0	N	2	1 joint	0 joints	NA		0.1

AC, anterior chamber; ANA, antinuclear antibodies; Anterior chamber cells (from SUN workshop[10]: Grade cells in field 0<1, 0.5+  = 1–5, 1+  = 6–15, 2+  = 16–25, 3+  = 26–50, 4+  = 50; BIO, bioscore; CMO, cystoid macular oedema; HLA, human leucocyte antigen; Intravit, intravitreal steroid; JIA, juvenile idiopathic arthritis; LE, left eye; NA, patient did not receive treatment to this time period; RE right eye; ST subtenons steroid; unchanged, active, inactive and improved are clinical assessments of uveitis activity taken from the SUN workshop[10]; VA, visual acuity; Vit'y, vitrectomy.

*Patient treated for 9 months.

†Patient treated for 12 months.

‡Pre‐existing visual loss not related to uveitis.